Peripheral neuropathy in prediabetes and the metabolic syndrome

Peripheral neuropathy is a major cause of disability worldwide. Diabetes is the most common cause of neuropathy, accounting for 50% of cases. Over half of people with diabetes develop neuropathy, and diabetic peripheral neuropathy (DPN) is a major cause of reduced quality of life due to pain, sensory loss, gait instability, fall‐related injury, and foot ulceration and amputation. Most patients with non‐diabetic neuropathy have cryptogenic sensory peripheral neuropathy (CSPN). A growing body of literature links prediabetes, obesity and metabolic syndrome to the risk of both DPN and CSPN. This association might be particularly strong in type 2 diabetes patients. There are no effective medical treatments for CSPN or DPN, and aggressive glycemic control is an effective approach to neuropathy risk reduction only in type 1 diabetes. Several studies suggest lifestyle‐based treatments that integrate dietary counseling with exercise might be a promising therapeutic approach to early DPN in type 2 diabetes and CSPN associated with prediabetes, obesity and metabolic syndrome. Over half of people with diabetes develop neuropathy, and diabetic neuropathy (DPN) is a major cause of reduced quality of life. A growing body of literature links prediabetes, obesity and metabolic syndrome (MetS) to neuropathy risk in patients with and without diabetes, particularly in type 2 diabetes. Several studies suggest lifestyle based treatments that integrate dietary counseling with exercise may be a promising therapeutic approach to cryptogenic sensory peripheral neuropathy (CSPN) in the setting of prediabetes and metabolic syndrome.